Sarepta Therapeutics Inc (SRPT)
Cash conversion cycle
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 835.02 | 861.79 | 958.33 | 821.89 | 783.83 | 650.26 | 591.95 | 515.29 | 531.82 | 572.86 | 610.44 | 684.28 | 700.34 | 1,200.46 | 1,237.34 | 1,199.92 | 1,335.80 | 1,420.87 | 1,201.68 | 1,106.07 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash conversion cycle | days | 835.02 | 861.79 | 958.33 | 821.89 | 783.83 | 650.26 | 591.95 | 515.29 | 531.82 | 572.86 | 610.44 | 684.28 | 700.34 | 1,200.46 | 1,237.34 | 1,199.92 | 1,335.80 | 1,420.87 | 1,201.68 | 1,106.07 |
December 31, 2024 calculation
Cash conversion cycle = DOH + DSO – Number of days of payables
= 835.02 + — – —
= 835.02
The cash conversion cycle for Sarepta Therapeutics Inc has shown some fluctuations over the years, indicating the company's efficiency in managing its working capital.
From March 31, 2020, to December 31, 2021, the cash conversion cycle ranged from a high of 1,420.87 days to a low of 700.34 days. This suggests that the company took a longer period to convert its resources into cash in certain quarters, possibly facing challenges in managing its receivables, inventory, and payables effectively.
However, starting from March 31, 2022, the cash conversion cycle began to improve significantly, declining consistently to 531.82 days by December 31, 2022. This trend indicates that Sarepta Therapeutics Inc enhanced its working capital management, resulting in a shorter period to convert its investments in inventory and accounts receivable into cash.
Despite a slight increase in the cash conversion cycle in the subsequent quarters through December 31, 2024, the overall trend remains positive, suggesting the company's continued efforts in optimizing its working capital efficiency.
It is important for Sarepta Therapeutics Inc to sustain this improvement in its cash conversion cycle to ensure better liquidity and operational stability in the future.
Peer comparison
Dec 31, 2024